Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 2—February 2008
Research

Cost-effectiveness of Human Papillomavirus Vaccination in the United States

Harrell W. Chesson*Comments to Author , Donatus U. Ekwueme*, Mona Saraiya*, and Lauri E. Markowitz*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 4

Summary of previously published models and estimates of the cost per QALY gained by adding routine HPV vaccination of 12-y-old girls to existing cervical cancer screening in the United States*†

Variable Goldie et al. 2004 (10) Sanders and Taira 2003 (11) Taira et al. 2004 (13) Elbasha et al. 2007 (9)
Key assumptions in published models
Target of HPV vaccine HPV 16,18 High risk HPV types HPV 16,18 HPV 6,11,16,18
Efficacy of vaccine 90% 75% 90% 100%‡
Vaccine cost per series $393 $300 $300 + $100 booster $360
Base year of $US
 2002
 2001
 2001
 2005
Estimated cost per QALY of vaccination
Published model estimate $24,300 $12,700§ $14,600 $3,000
Simplified model estimate $20,600 $8,700 $17,100 $5,300

*QALY, quality-adjusted life year; HPV, human papillomavirus.
†In all comparisons, the simplified model was modified (as necessary) so that the assumptions regarding the target of the HPV vaccine, vaccine efficacy and cost, vaccine duration of protection (except in the comparison to Taira and colleagues [13], as noted in the Technical Appendix, and the base year of US$ were consistent with the published models (Technical Appendix). The simplified model estimate was based on the cohort model in the comparisons with the findings of Goldie et al. (10) and Sanders and Taira (11) and was based on the population model (assuming transmission effects) in the comparison with the estimates of Taira and colleagues (13) and Elbasha and colleagues (9).
‡Elbasha and colleagues (9) assumed 90% protection against infection with HPV and 100% protection against HPV-related disease.§To enhance comparability, the published estimate from Sanders and Taira (11) was based on their sensitivity analyses when assuming lifetime duration of vaccination, not their base-case estimate of $22,800 when 10-y vaccine duration of protection was assumed.

Main Article

References
  1. Institute of Medicine. Vaccines for the 21st century: a tool for decisionmaking. Washington: National Academy of Sciences; 2000.
  2. Parkin  DM, Bray  F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S11–25. DOIPubMedGoogle Scholar
  3. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.
  4. Clifford  GM, Smith  JS, Aguado  T, Franceschi  S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101–5. DOIPubMedGoogle Scholar
  5. Dunne  EF, Markowitz  LE. Genital human papillomavirus infection. Clin Infect Dis. 2006;43:624–9. DOIPubMedGoogle Scholar
  6. Greer  CE, Wheeler  CM, Ladner  MB, Beutner  K, Coyne  MY, Liang  H, Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058–63.PubMedGoogle Scholar
  7. Chesson  HW, Blandford  JM, Gift  TL, Tao  G, Irwin  KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004;36:11–9. DOIPubMedGoogle Scholar
  8. Insinga  RP, Dasbach  EJ, Elbasha  EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23:1107–22. DOIPubMedGoogle Scholar
  9. Elbasha  EH, Dasbach  EJ, Insinga  RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41.PubMedGoogle Scholar
  10. Goldie  SJ, Kohli  M, Grima  D, Weinstein  MC, Wright  TC, Bosch  FX, Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15.PubMedGoogle Scholar
  11. Sanders  GD, Taira  AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37–48.PubMedGoogle Scholar
  12. Kulasingam  SL, Myers  ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781–9. DOIPubMedGoogle Scholar
  13. Taira  AV, Neukermans  CP, Sanders  GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915–23.PubMedGoogle Scholar
  14. Dasbach  EJ, Elbasha  EH, Insinga  RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88–100. DOIPubMedGoogle Scholar
  15. Gold  MR, Siegel  JE, Russell  LB, Weinstein  MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
  16. Haddix  AC, Teutsch  SM, Corso  PS, eds. Prevention effectiveness: a guide to decision analysis and economic evaluation, 2nd ed. New York: Oxford University Press; 2003.
  17. U.S. Census Bureau. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2005 (NC-EST2005–01). Population Division, US Census Bureau; 2006 [cited 2007 Aug 8]. Available from http://www.census.gov/popest/national/asrh/NC-EST2005-sa.html
  18. Koutsky  LA, Ault  KA, Wheeler  CM, Brown  DR, Barr  E, Alvarez  FB, A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–51. DOIPubMedGoogle Scholar
  19. Mao  C, Koutsky  LA, Ault  KA, Wheeler  CM, Brown  DR, Wiley  DJ, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18–27.PubMedGoogle Scholar
  20. Villa  LL, Costa  RL, Petta  CA, Andrade  RP, Ault  KA, Giuliano  AR, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–8. DOIPubMedGoogle Scholar
  21. Harper  DM, Franco  EL, Wheeler  CM, Moscicki  AB, Romanowski  B, Roteli-Martins  CM, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55. DOIPubMedGoogle Scholar
  22. US Cancer Statistics Working Group. United States cancer statistics: 2003 incidence and mortality. Atlanta: Centers for Disease Control and Prevention and National Cancer Institute; 2006.
  23. Hankey  BF, Ries  LA, Edwards  BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117–21.PubMedGoogle Scholar
  24. Watson  M, Saraiya  M, Weir  H, Ahmed  F. Leading partnerships to assess the burden of HPV-related cancers. 2007 CDC Cancer Conference Program of Events; 2007 Aug 13–17; Atlanta. Atlanta: Centers for Disease Control and Prevention; 2007. Abstract 005.
  25. Insinga  RP, Glass  AG, Rush  BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191:105–13. DOIPubMedGoogle Scholar
  26. Insinga  RP, Dasbach  EJ, Myers  ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397–403. DOIPubMedGoogle Scholar
  27. Alam  M, Stiller  M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001;137:337–41.PubMedGoogle Scholar
  28. Insinga  RP, Glass  AG, Rush  BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191:114–20. DOIPubMedGoogle Scholar
  29. Brown  AD, Garber  AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA. 1999;281:347–53. DOIPubMedGoogle Scholar
  30. Maxwell  GL, Carlson  JW, Ochoa  M, Krivak  T, Rose  GS, Myers  ER. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol. 2002;100:740–8. DOIPubMedGoogle Scholar
  31. Goldie  SJ, Kim  JJ, Wright  TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619–31.PubMedGoogle Scholar
  32. Mandelblatt  JS, Lawrence  WF, Womack  SM, Jacobson  D, Yi  B, Hwang  Y, Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:2372–81. DOIPubMedGoogle Scholar
  33. Goldie  SJ, Kuntz  KM, Weinstein  MC, Freedberg  KA, Palefsky  JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med. 2000;108:634–41. DOIPubMedGoogle Scholar
  34. British Columbia Cancer Agency, Cancer Prevention Program. A population-based HPV immunization program in British Columbia: background paper. Vancouver (BC): The Agency; 2006.
  35. Lang  K, Menzin  J, Earle  CC, Jacobson  J, Hsu  M. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130:1269–75. DOIPubMedGoogle Scholar
  36. Gold  MR, Franks  P, McCoy  KI, Fryback  DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778–92. DOIPubMedGoogle Scholar
  37. Kim  JJ, Wright  TC, Goldie  SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382–90. DOIPubMedGoogle Scholar
  38. Schiffman  M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111:145–53. DOIPubMedGoogle Scholar
  39. Kulasingam  SL, Myers  ER, Lawson  HW, McConnell  KJ, Kerlikowske  K, Meinikow  J, Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol. 2006;107:321–8.PubMedGoogle Scholar
  40. Haupt  RM. GARDASIL update. 2007 CDC Cancer Conference Program of Events; 2007 Aug 13–17; Atlanta. Atlanta: Centers for Disease Control and Prevention.

Main Article

Page created: July 21, 2010
Page updated: July 21, 2010
Page reviewed: July 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external